Who is sponsoring NCT03832907?

NCT03832907 is sponsored by Emory University.

What drugs are being tested in NCT03832907?

Interventions in NCT03832907: Dexcom G6 CGM - Continues Glucose Monitoring sensor system, POC BG - Point-of-Care Blood Glucose monitoring.

Is NCT03832907 still recruiting?

NCT03832907 is currently completed. Last updated 5 August 2021.

Are results published for NCT03832907?

Yes — primary outcome results have been posted to ClinicalTrials.gov. See the outcomes section above for details.

Last reviewed 2021-08-05 · How we verify

NCT03832907

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Dexcom G6 Observational Study

Completed NA Results posted Last updated 5 August 2021

What this trial tests

NA trial testing Dexcom G6 CGM - Continues Glucose Monitoring sensor system in Diabetes in 101 participants. Completed in 31 March 2020.

Timeline

21 February 2019

Primary endpoint
31 March 2020

31 March 2020

Quick facts

Lead sponsor	Emory University
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	diagnostic
Enrollment	101
Start date	21 February 2019
Primary completion	31 March 2020
Estimated completion	31 March 2020
Sites	1 location across United States

Drugs / interventions tested

Dexcom G6 CGM - Continues Glucose Monitoring sensor system
POC BG - Point-of-Care Blood Glucose monitoring

Conditions studied

Diabetes — all drugs for Diabetes →

Sponsor

Emory University

Who can join

18 and older, any sex, with Diabetes. Patients with the condition only — healthy volunteers not accepted.

Results — posted to ClinicalTrials.gov

Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.

Mean Daily Blood Glucose by POC Reading сompared to CGM Reading Primary · During hospital stay (3 days - up to 30 days)

Mean daily blood glucose will be calculated

POC

Group	Value	95% CI
Dexcom G6 CGM - Continues Glucose Monitoring Sensor System	175.55	± 42.37

CGM

Group	Value	95% CI
Dexcom G6 CGM - Continues Glucose Monitoring Sensor System	175.84	± 42.35

Number of Clinical Significant Hypoglycemia (<54 mg/dl) Events by POC Reading Compared to CGM Reading Primary · During hospital stay (3 days - up to 30 days)

Number of clinical significant hypoglycemia (\<54 mg/dl) events will be calculated

POC

Group	Value	95% CI
Dexcom G6 CGM - Continues Glucose Monitoring Sensor System	9

CGM

Group	Value	95% CI
Dexcom G6 CGM - Continues Glucose Monitoring Sensor System	60

Number of Severe Hyperglycemia (>240 mg/dl) Events by POC Reading Compared to CGM Reading Primary · During hospital stay (3 days - up to 30 days)

Number of severe hyperglycemia (\>240 mg/dl) events will be recorded

POC

Group	Value	95% CI
Dexcom G6 CGM - Continues Glucose Monitoring Sensor System	305

CGM

Group	Value	95% CI
Dexcom G6 CGM - Continues Glucose Monitoring Sensor System	518

Mean Daily Blood Glucose by POC Reading Compared to CGM Reading Secondary · 10 days post discharge

Mean daily blood glucose will be calculated

POC

Group	Value	95% CI
Dexcom G6 CGM - Continues Glucose Monitoring Sensor System	175.55	± 42.37

CGM

Group	Value	95% CI
Dexcom G6 CGM - Continues Glucose Monitoring Sensor System	173.13	± 41.77

Number of Clinical Significant Hypoglycemia (<54 mg/dl) Events by POC Reading Compared to CGM Reading Secondary · 10 days post discharge

Number of clinical significant hypoglycemia (\<54 mg/dl) events will be calculated

POC

Group	Value	95% CI
Dexcom G6 CGM - Continues Glucose Monitoring Sensor System	9

CGM (arm)

Group	Value	95% CI
Dexcom G6 CGM - Continues Glucose Monitoring Sensor System	29

Number of Clinical Significant Severe Hyperglycemia (>240 mg/dl) Events by POC Reading Compared to CGM Reading Secondary · 10 days post discharge

Number of severe hyperglycemia (\>240 mg/dl) events will be recorded

POC

Group	Value	95% CI
Dexcom G6 CGM - Continues Glucose Monitoring Sensor System	305

CGM

Group	Value	95% CI
Dexcom G6 CGM - Continues Glucose Monitoring Sensor System	399

Number of Nocturnal Hypoglycemic Events < 70 mg/dl (Between 22:00 and 06:00) by POC Reading Compared to CGM Reading Secondary · During hospital stay (3 days - up to 30 days)

Number of nocturnal hypoglycemic events \< 70 mg/dl (between 22:00 and 06:00) will be recorded

POC

Group	Value	95% CI
Dexcom G6 CGM - Continues Glucose Monitoring Sensor System	1

CGM abdomen

Group	Value	95% CI
Dexcom G6 CGM - Continues Glucose Monitoring Sensor System	48

CGM arm

Group	Value	95% CI
Dexcom G6 CGM - Continues Glucose Monitoring Sensor System	34

Number of Nocturnal Hypoglycemic Events < 70 mg/dl (Between 22:00 and 06:00) by POC Reading Compared to CGM Reading Secondary · 10 days post discharge

Number of nocturnal hypoglycemic events \< 70 mg/dl(between 22:00 and 06:00) will be recorded

POC

Group	Value	95% CI
Dexcom G6 CGM - Continues Glucose Monitoring Sensor System	1

CGM abdomen

Group	Value	95% CI
Dexcom G6 CGM - Continues Glucose Monitoring Sensor System	22

CGM arm

Group	Value	95% CI
Dexcom G6 CGM - Continues Glucose Monitoring Sensor System	9

Number of of Hypoglycemic Events < 70mg/dl in POC Group by POC Reading Compared to CGM Reading Secondary · During hospital stay (3 days - up to 30 days)

Number of of hypoglycemic events \< 70mg/dl will be recorded

POC

Group	Value	95% CI
Dexcom G6 CGM - Continues Glucose Monitoring Sensor System	36

CGM abdomen

Group	Value	95% CI
Dexcom G6 CGM - Continues Glucose Monitoring Sensor System	144

CGM arm

Group	Value	95% CI
Dexcom G6 CGM - Continues Glucose Monitoring Sensor System	115

Number of Hypoglycemic Events < 70mg/dl by POC Reading Compared to CGM Reading Secondary · 10 days post discharge

Number of of hypoglycemic events \< 70mg/dl will be recorded

POC

Group	Value	95% CI
Dexcom G6 CGM - Continues Glucose Monitoring Sensor System	10

CGM abdomen

Group	Value	95% CI
Dexcom G6 CGM - Continues Glucose Monitoring Sensor System	100

CGM arm

Group	Value	95% CI
Dexcom G6 CGM - Continues Glucose Monitoring Sensor System	48

Time in Hypoglycemia (Minutes) During the Day and Night by CGM Reading Secondary · During hospital stay (3 days - up to 30 days)

Time in hypoglycemia (minutes) during the day and night will be recorded. Only measured by CGM, Discrete POC values are not used to assess amount of time spent within a specific glucose range. .

CGM abdomen)

Group	Value	95% CI
Dexcom G6 CGM - Continues Glucose Monitoring Sensor System	119.08	± 216.56

CGM arm

Group	Value	95% CI
Dexcom G6 CGM - Continues Glucose Monitoring Sensor System	78.63	± 135.33

Time in Hypoglycemia (Minutes) During the Day and Night by CGM Reading Secondary · 10 days post discharge

Time in hypoglycemia (minutes) during the day and night will be recorded. Only measured by CGM, Discrete POC values are not used to assess amount of time spent within a specific glucose range. .

CGM abdomen

Group	Value	95% CI
Dexcom G6 CGM - Continues Glucose Monitoring Sensor System	118.70	± 217.83

CGM arm

Group	Value	95% CI
Dexcom G6 CGM - Continues Glucose Monitoring Sensor System	89.14	± 140.16

Adverse events — posted to ClinicalTrials.gov

Time frame: 1 month. Reporting threshold: 0%. Adverse-event reports describe events observed during the trial — not all are caused by the drug.

Dexcom G6 CGM - Continues Glucose Monitoring Sensor System

Serious: 0/101 (0%)

Deaths: 0/101

Other adverse events (1 terms — click to expand)

Reaction	System	Dexcom G6 CGM - Continues …
Sensor site irritation/bleeding	Injury, poisoning and procedural complications	—

Data from ClinicalTrials.gov NCT03832907 adverse events section.

Sponsor's own description

This is an exploratory prospective study primary aiming to evaluate differences between Point-of-care (POC) testing (standard of care) and Dexcom G6 CGM (Continues Glucose Monitoring sensor system) in 1) glycemic control measured by mean daily blood glucose and 2) identifying hypoglycemic and hyperglycemic events - in patients with type 1 and type 2 diabetes treated with basal bolus insulin regimen.

Publications & conference data

4 peer-reviewed publications reference this trial (live from Europe PMC):

Accuracy of Dexcom G6 Continuous Glucose Monitoring in Non-Critically Ill Hospitalized Patients With Diabetes.
Davis GM, Spanakis EK, Migdal AL, Singh LG, et al · · 2021 · cited 102× · PMID 34099515 · DOI 10.2337/dc20-2856
Remote Continuous Glucose Monitoring With a Computerized Insulin Infusion Protocol for Critically Ill Patients in a COVID-19 Medical ICU: Proof of Concept.
Davis GM, Faulds E, Walker T, Vigliotti D, et al · · 2021 · cited 79× · PMID 33563655 · DOI 10.2337/dc20-2085
Diabetes Technology in the Inpatient Setting for Management of Hyperglycemia.
Davis GM, Galindo RJ, Migdal AL, Umpierrez GE. · · 2020 · cited 40× · PMID 31980123 · DOI 10.1016/j.ecl.2019.11.002
A Randomized Controlled Trial Comparing Glargine U300 and Glargine U100 for the Inpatient Management of Medicine and Surgery Patients With Type 2 Diabetes: Glargine U300 Hospital Trial.
Pasquel FJ, Lansang MC, Khowaja A, Urrutia MA, et al · · 2020 · cited 24× · PMID 32273271 · DOI 10.2337/dc19-1940

Verify or expand the search:

Other trials of Dexcom G6 CGM - Continues Glucose Monitoring sensor system

Trials testing the same drug.

NCT03877068 — Dexcom G6 Intervention Study · NA · completed

Other recruiting trials for Diabetes

Currently open trials in the same condition.

NCT07272837 — Impact of Semaglutide (Ozempic/Wegovy®) on Heart and Muscle Mass · recruiting
NCT07479134 — Production of Stem Cells for the Generation of Pancreatic Cells · NA · recruiting
NCT07441655 — Families Implementing Good Health Traditions for Life · NA · recruiting
NCT06724172 — CHIME: Comparing Health Interventions for Maternal Equity · NA · recruiting
NCT07417865 — ECHO Diabetes FQHC · recruiting

Other Emory University trials

Trials by the same sponsor.

NCT06143345 — HIIT in Isolated IFG: A Proof-of-Concept Study · NA · withdrawn
NCT07189819 — Innovative Closed-loop Functional Electrical Stimulation Control System for Augmenting Post-stroke Gait · NA · not yet recruiting
NCT06451055 — Low-calorie Diet in Isolated Impaired Fasting Glucose · NA · not yet recruiting
NCT07405476 — Zanidatamab Before Surgery for the Treatment of HER2 Positive Colon and Rectal Cancer in Patients Planned for Curative I · Phase 2 · recruiting
NCT06708351 — Enhancing Cervical Cancer Screening and Treatment in Women Living With HIV in Kenya, the ENHANCE LINKAge Trial · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03832907 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Emory University
Last refreshed: 5 August 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03832907.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing

NCT03832907

Quick facts

Drugs / interventions tested

Conditions studied

Sponsor

Who can join

Results — posted to ClinicalTrials.gov

Adverse events — posted to ClinicalTrials.gov

Sponsor's own description

Publications & conference data

Related trials

Other trials of Dexcom G6 CGM - Continues Glucose Monitoring sensor system

Other recruiting trials for Diabetes

Other Emory University trials

Verify against primary sources